Rigel Pharma (NASDAQ: RIGL) reported Q2 EPS of ($0.16), in-line with the analyst estimate of ($0.16). Revenue for the quarter came in at $1.8 million.

As of June 30, 2018, Rigel had cash, cash equivalents and short-term investments of $135.0 million, compared to $115.8 million as of December 31, 2017. Rigel expects that its cash, cash equivalents and short-term investments will be sufficient to support its current and projected funding requirements, including the on-going commercial launch of TAVALISSE for chronic ITP in the U.S., into the fourth quarter of 2019.

For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.